Clinical trial NCT06905834: Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
Official title: A Phase IIB Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Dry Eye Disease (DED)
Graft-Versus-Host Disease(GVHD)
Keywords: dry eye disease
Graft-versus-Host Disease
mesenchymal stem cells
Lead sponsor: Instituto de Investigación Biomédica de Salamanca
Sponsor class: OTHER
Collaborators: name: Spanish Clinical Research Network - SCReN
name: Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
First posted: 2025-04-01
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This Phase IIB, multicenter, double-blind, randomized, and uncontrolled clinical trial aims to assess the efficacy and safety of subconjunctival injection of Mesenchymal Stem Cells (MSCs) in patients with Graft-versus-Host Disease (GVHD) and severe ocular involvement (DYD-dry eye disease). The primary objective is to evaluate the clinically and statistically significant improvement in the signs and symptoms associated with the disease.

Secondary objectives include:

* Analyzing adverse events related to the subconjunctival injection of MSCs to confirm the safety of this treatment in patients with GVHD ocular involvement.
* Identifying new biomarkers that can be used to objectively assess the progression of patients with GVHD and severe ocular involvement.
* Studying the relationship between the expression of ocular surface-specific markers by MSCs and their clinical efficacy, as well as the variation in the expression of these markers in relation to cell preservation methods.

Assessing the quality of life of patients treated with two doses of MSCs using the NEI VFQ-25 (National Eye Institute Visual Function Questionnaire).

- Evaluating whether the cell dose impacts clinical improvement.

The trial includes 30 patients, divided into two groups of 15, and focuses on the assessment of dry eye disease, with the treatment based on MSC administration to improve clinical outcomes and quality of life for the patients.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age who understand and sign the informed consent form.
* Diagnosis of severe GVHD (graft versus host disease) according to NIH criteria (revised by Lee SJ in 2017) with ocular involvement in the form of severe SOD (severe ocular disease) in both eyes for more than 3 months, objectively defined as superficial punctate keratitis \>2 on the Oxford scale (range 0-5) and/or the presence of epithelial defect, and subjectively as severe symptoms, \>33 points on the OSDI questionnaire (0-100).
* Patients must have previously been treated for at least three months with blood derivatives and/or insulin eye drops and topical cyclosporine or tacrolimus (unless any of these treatments were not tolerated and had to be discontinued).
* Patients must be using ocular lubricants at least 4 times a day and, despite this, still meet the criteria for severe SOD as outlined in point 2.
* Patients on low doses of topical corticosteroids for maintenance should have a stable dose for at least one month prior to inclusion.
* The dose and frequency of all topical medications the patient begins the trial with must remain unchanged throughout the duration of the trial, unless otherwise judged by the investigator.
* The chronic GVHD systemic treatment should be stable regarding the use of systemic immunosuppressors for at least one month prior to patient inclusion or before starting treatment.
* Negative result in the urine pregnancy test at the baseline visit for women of childbearing age. Subjects must be advised to use contraceptive methods during their participation in the clinical trial and undergo a new pregnancy test at the treatment visit if more than 28 days have passed since the baseline visit.

Exclusion Criteria:

* Uncontrolled systemic disease or any condition that, in the medical judgment, could put the patient at risk or affect the interpretation of the results.
* Uncontrolled systemic GVHD.
* Active ocular infection.
* Ocular surgery within the last 3 months.
* Initiation of topical therapies for SOD indicated in the inclusion criteria less than 3 months prior to inclusion.
* Start of topical corticosteroid use within 4 weeks prior to inclusion.
* Cognitive impairments that could interfere with study compliance.
* Pregnant women or women during the lactation period.

Primary outcomes:
measure: Change in the integrity of the ocular surface
timeFrame: six and twelve months from start of treatment
measure: Change in tear production
timeFrame: six and twelve months from start of treatment
measure: Change in the degree of conjunctival hyperemia
timeFrame: six and twelve months from start of treatment
measure: Change in the parameters related to the Meibomian glands
timeFrame: six and twelve months from start of treatment
measure: Change in any of the findings in the central cornea
timeFrame: six and twelve months from start of treatment
measure: Severity of eye disease measured by WFPRS (Wong-Baker Faces Pain Rating Scale)
timeFrame: six and twelve months from start of treatment
measure: Severity of eye disease measured by Numerical Rating Scale (NRS)
timeFrame: six and twelve months from start of treatment
measure: Severity of eye disease measured by Modified Symptom Assessment in Dry Eye Questionnaire (mSIDEQ)
timeFrame: six and twelve months from start of treatment
measure: Severity of eye disease measured by Ocular Surface Disease Index (OSDI)
timeFrame: six and twelve months from start of treatment
measure: Severity of eye disease measured by CDES-Q (Contact Lens Dry Eye Symptom Questionnaire)
timeFrame: six and twelve months from start of treatment
Secondary outcomes:
measure: Rate of adverse events related to the administration of subconjunctival ASC injection.
timeFrame: Through study completion, an average of 1 year
measure: Analysis of ocular marker expression in the administered ASCs
timeFrame: When vials are thawed before treating the first patients with 6.25 mill and 12.5 mill ASC, 1 year afterwards and two years afterwards or altertatively, when vials are thawed to treat the last patient with 6.25 and 12.5 mill ASC.
measure: Analysis of the presence and concentration of inflammation-related molecules in tear and serum samples
timeFrame: Visit 2 (day 14 ± 7 after screening), 6 months, 12 months and when applicable, at premature withdrawal.
measure: Search for new biomarkers that can be used to objectively evaluate the progression of patients affected by EICRc with ocular involvement.
timeFrame: Visit 2 (day 14 ± 7 after screening), 6 months, 12 months and when applicable, at premature withdrawal.
Other outcomes:
Locations:
Study officials:
affiliation: Centro Asistencial Universitario de Salamanca (CAUSA)
name: Fermín Sánchez-Guijo Martín MD, PhD, Medical Degree in Haematology
role: STUDY_DIRECTOR
affiliation: Centro Asistencial Universitario de Salamanca (CAUSA)
name: Lourdes Vázquez López MD, PhD, Medical Degree in Haematology
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospital General Universitario Gregorio Marañón (HGUGM)
name: Mi Kwon MD, PhD, Medical Degree in Haematology
role: PRINCIPAL_INVESTIGATOR
References: